Blockade of Na+ Channels in Pancreatic α-Cells Has Antidiabetic Effects
The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index.
Abstract
Pancreatic α-cells express voltage-gated Na+ channels (NaChs), which support the generation of electrical activity leading to an increase in intracellular calcium, and cause exocytosis of glucagon. Ranolazine, a NaCh blocker, is approved for treatment of angina. In addition to its antianginal effects, ranolazine has been shown to reduce HbA1c levels in patients with type 2 diabetes mellitus and coronary artery disease; however, the mechanism behind its antidiabetic effect has been unclear. We tested the hypothesis that ranolazine exerts its antidiabetic effects by inhibiting glucagon release via blockade of NaChs in the pancreatic α-cells. Our data show that ranolazine, via blockade of NaChs in pancreatic α-cells, inhibits their electrical activity and reduces glucagon release. We found that glucagon release in human pancreatic islets is mediated by the Nav1.3 isoform. In animal models of diabetes, ranolazine and a more selective NaCh blocker (GS-458967) lowered postprandial and basal glucagon levels, which were associated with a reduction in hyperglycemia, confirming that glucose-lowering effects of ranolazine are due to the blockade of NaChs. This mechanism of action is unique in that no other approved antidiabetic drugs act via this mechanism, and raises the prospect that selective Nav1.3 blockers may constitute a novel approach for the treatment of diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ranolazine appears to reduce HbA1c by ≈0.5% to 0.7% via a reduction in glucagon secretion”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [258]
Citations
Cites
共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages
Herrera, P. L. (2000) · Development · doi:10.1242/dev.127.11.2317 · Cited by 672
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649 · cited 1×
“The effect was similar to that reported with GLP-1 receptor agonists, which also inhibit glucagon secretion, albeit via a different mechanism (27).”
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 3×
“Glucagon as a Target for Diabetes The abnormal glucagon secretion in T2DM and its key role in the development of fasting and postprandial hyperglycemia has recently been a focus of attention (1,7,29).”
InfluentialChaitman, B. R., Skettino, S. L., Parker, J. O., Hanley, P., Meluzin, J., Kuch, J., Pepine, C. J., Wang, W., Nelson, J. J., Hebert, D. A., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.045 · Cited by 567 · cited 1×
“Ranolazine is an anti-anginal drug with cardioprotective properties (12).”
BackgroundBelardinelli, L., Shryock, J. C., & Fraser, H. (2006) · Heart · doi:10.1136/hrt.2005.078790 · Cited by 386
Self-citationShah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368 · cited 1×
“This hyperglucagonemia increases hepatic glucose production, thereby contributing importantly to diabetic hyperglycemia (4,5).”
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 1×
“Therefore, suppression of glucagon secretion or inhibition of its action in the liver constitutes potential therapeutic targets for diabetes (30-32).”
REAVEN, G. M., CHEN, Y.-D. I., GOLAY, A., SWISLOCKI, A. L. M., & JASPAN, J. B. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-106 · Cited by 326 · cited 1×
“Plasma glucagon levels are increased under both fasting and postprandial states in diabetes (2,3).”
MacDonald, P. E., Marinis, Y. Z. D., Ramracheya, R., Salehi, A., Ma, X., Johnson, P. R. V., Cox, R., Eliasson, L., & Rorsman, P. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050143 · Cited by 246 · cited 1×
“These findings are consistent with previous reports demonstrating that NaChs can directly modulate glucagon secretion in intact islets obtained from non-diabetic rodents and humans (8-11, 22, 23).”
Result
Research works printed but not linked: 1
- Prince, 2011, Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose (FBG) and HbA1c in patients with type 2 diabetes mellitus, Diabetologia, 54, S86
Cited by
Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications
de Lera Ruiz, M., & Kraus, R. L. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501981g · Cited by 548
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
A method for the generation of human stem cell-derived alpha cells
Peterson, Q. P., Veres, A., Chen, L., Slama, M. Q., Kenty, J. H. R., Hassoun, S., Brown, M. R., Dou, H., Duffy, C. D., Zhou, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16049-3 · Cited by 92
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 94
Cassano, V., Leo, A., Tallarico, M., Nesci, V., Cimellaro, A., Fiorentino, T. V., Citraro, R., Hribal, M. L., Sarro, G. D., Perticone, F., et al. (2020) · Nutrients · doi:10.3390/nu12020382 · Cited by 69
Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Eckel, R. H., Henry, R. R., Yue, P., Dhalla, A. K., Wong, P., Jochelson, P., Belardinelli, L., & Skyler, J. S. (2015) · Diabetes Care · doi:10.2337/dc14-2629 · Cited by 57
“In animal models of diabetes, ranolazine lowered postprandial and basal glucagon levels, which were associated with a reduction in hyperglycemia and lowering of HbA1c (13).”
BackgroundInfluentialSelf-citationSodium channel NaV1.3 is important for enterochromaffin cell excitability and serotonin release
Strege, P. R., Knutson, K. R., Eggers, S. J., Li, J. H., Wang, F., Linden, D. R., Szurszewski, J. H., Milescu, L. S., Leiter, A. B., Farrugia, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15834-3 · Cited by 57
Drug Interactions of Metformin Involving Drug Transporter Proteins
Maideen, N. M. P., Jumale, A. H., & Balasubramaniam, R. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.062 · Cited by 60
“Ranolazine blocks sodium channel of pancreatic α cells and decreases electrical activity to inhibit glucagon release.(39) The plasma concentrations of Metformin may be elevated by the co-administration of Ranolazine which may decrease the Metformin elimination through the inhibition of OCT2 transporter.”
BackgroundThe Role of Glucagon in the Pathophysiology and Management of Diabetes
Kulina, G., & Rayfield, E. J. (2016) · Endocrine Practice · doi:10.4158/ep15984.ra · Cited by 51
So, E. C., Wu, S., Lo, Y., & Su, K. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.01.002 · Cited by 42
The influence of sodium on pathophysiology of multiple sclerosis
Zostawa, J., Adamczyk-Zostawa, J., Sowa, P., & Adamczyk-Sowa, M. H. (2017) · Neurological Sciences · doi:10.1007/s10072-016-2802-8 · Cited by 34
Ren, L., Chen, X., Nie, B., Qu, H., Ju, J., & Bai, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.806966 · Cited by 28
“Ranolazine lowers the levels of glycated hemoglobin and fasting blood glucose, and it inhibits the release of glucagon in diabetic patients, which has a positive effect on the treatment of diabetes (Chisholm et al., 2010; Dhalla et al., 2014; Eckel et al., 2015).”
BackgroundRole of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina
Banerjee, K., Ghosh, R. K., Kamatam, S., Banerjee, A., & Gupta, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.102 · Cited by 27
Yang, L., Li, Q., Liu, X., & Liu, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091479 · Cited by 33
“3 blockers might provide a novel approach for the treatment of diabetes [68].”
BackgroundElkholy, S. E., Elaidy, S. M., El-Sherbeeny, N. A., Toraih, E. A., & El-Gawly, H. W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117557 · Cited by 27
Dusaulcy, R., Handgraaf, S., Visentin, F., Vesin, C., Philippé, J., & Gosmain, Y. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.01.004 · Cited by 20
Diabetogenic effects of cardioprotective drugs
Bell, D. S. H., & Gonçalves, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14295 · Cited by 23
Tamargo, J. L., & Lopez-Sendon, J. L. (2021) · Future Cardiology · doi:10.2217/fca-2021-0058 · Cited by 22
Ranolazine: Multifaceted role beyond coronary artery disease, a recent perspective
Ghosh, G. C., Ghosh, R., Bandyopadhyay, D., Chatterjee, K., & Aneja, A. (2018) · Heart Views · doi:10.4103/heartviews.heartviews_18_18 · Cited by 22
“Studies have also revealed its role in pancreatic beta-cell preservation[7,8] [Figure 1].”
BackgroundFanaroff, A. C., James, S. K., Weisz, G., Prather, K. O., Anstrom, K. J., Mark, D. B., Ben‐Yehuda, O., Alexander, K. P., Stone, G. W., & Ohman, E. M. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.056 · Cited by 18
“Ranolazine preserves pancreatic b-cell mass in streptozocin-treated mice by unclear molecular mechanisms (20), reduces glucagon secretion via inhibition of sodium channels (8), and diminishes fatty acid oxygenation in the liver, shifting the liver’s energy source from fatty acids to glucose (21).”
BackgroundBatran, R. A., Gopal, K., Aburasayn, H., Eshreif, A., Almutairi, M. G., Greenwell, A. A., Campbell, S. A., Saleme, B., Court, E. A., Eaton, F., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124643 · Cited by 19
Qi, M., Luis, V., Bilbao, S., Omori, K., Rawson, J., McFadden, B., Juan, J., Nair, I., Mullen, Y., El-Shahawy, M. A., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00443.2014 · Cited by 16
Pettus, J., McNabb, B., Eckel, R. H., Skyler, J. S., Dhalla, A. K., Guan, S., Jochelson, P., Belardinelli, L., & Henry, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12629 · Cited by 17
Self-citationCaminiti, G., FOSSATI, C., Battaglia, D., Massaro, R., Rosano, G. M. C., & Volterrani, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.003 · Cited by 16
Ranolazine and Its Effects on Hemoglobin A 1C
Greiner, L., Hurren, K. M., & Brenner, M. J. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016631757 · Cited by 15
“A second proposed mechanism for reduction of A1C with ranolazine is the blockade of sodium channels in pancreatic alpha-cells.(19) Pancreatic alpha-cells secrete glucagon, which regulates glucose homeostasis through the promotion of hepatic glucose production.”
BackgroundNusca, A., Bernardini, F., Mangiacapra, F., Maddaloni, E., Melfi, R., Ricottini, E., Piccirillo, F., Manfrini, S., Ussia, G. P., & Grigioni, F. (2021) · Journal of Diabetes Research · doi:10.1155/2021/4952447 · Cited by 18
“However, the blockage of late sodium channels by this drug has also been reported in other tissues such as pancreatic islets [3].”
BackgroundThe Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population
Lisi, D., Andrews, E., Parry, C., Hill, C., Ombengi, D., & Ling, H. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06917-6 · Cited by 14
Efficacy and Safety of Ranolazine in Diabetic Patients: A Systematic Review and Meta-analysis
Zeng, X., Zhang, Y., Lin, J.-H., Zheng, H., Peng, J., & Huang, W. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017747901 · Cited by 15
Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus
Gilbert, B. W., Sherard, M. K., Little, L., Branstetter, J. W., Meister, A., & Huffman, J. B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.11.021 · Cited by 13
Late sodium current (INaL) in pancreatic β-cells
Rizzetto, R., Rocchetti, M., Sala, L., Ronchi, C., Villa, A., Ferrandi, M., Molinari, I., Bertuzzi, F., & Zaza, A. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1613-0 · Cited by 15
Ambrosio, G., Tamargo, J. L., & Grant, P. J. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115609028 · Cited by 11
Glucagon – the new ‘insulin’ in the pathophysiology of diabetes
Farhy, L. S., & McCall, A. L. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000192 · Cited by 10
Teoh, I. H., & Banerjee, M. (2018) · Open Heart · doi:10.1136/openhrt-2017-000706 · Cited by 9
Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis
Manolis, A. J., Kallistratos, M. S., Poulimenos, L. E., Zamfir, T., & Thomopoulos, C. (2022) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2022.12.002 · Cited by 9
Glucagonotropic and Glucagonostatic Effects of KATP Channel Closure and Potassium Depolarization
Früh, E., Elgert, C., Eggert, F., Scherneck, S., & Rustenbeck, I. (2020) · Endocrinology · doi:10.1210/endocr/bqaa136 · Cited by 9
Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease
Cacciapuoti, F. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716636042 · Cited by 8
Functional Studies of Sodium Channels: From Target to Compound Identification
Bertrand, D., Biton, B., Licher, T., Chambard, J., Lanneau, C., Partiseti, M., & Lefevre, I. A. (2016) · Current Protocols in Pharmacology · doi:10.1002/cpph.14 · Cited by 9
“3-blocking drugs acting preferentially, such as ranolazine or GS-458967, on the late component of the sodium current could be an innovative means to maintain physiological blood glucose in type II diabetic patients (Dhalla et al., 2014; Tan et al., 2015).”
BackgroundAnti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes
Manolis, A. J., Kallistratos, M. S., Poulimenos, L. E., & Thomopoulos, C. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.12.001 · Cited by 7
Tentolouris, K. N., Anastasiou, I. A., Mourouzis, I. S., Pantos, C. I., & Tentolouris, N. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x356362250324080014 · Cited by 5
Contemporary Antianginal Therapy
Patel, S. Y., Patel, V. H., Ayyad, M., Palani, A., & Allencherril, J. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00766-5 · Cited by 6
“While the mechanism of ranolazine’s glucose-lowering properties is not fully understood, animal models suggest blockade of voltage-gated sodium channels in pancreatic alpha cells, leading to reduced glucagon secretion [56].”
Kayan, F., & Savaş, H. B. (2025) · Scientific Reports · doi:10.1038/s41598-025-08099-8 · Cited by 3
Non-coding RNAs modulate pyroptosis in diabetic cardiomyopathy: A comprehensive review
Shang, W., Geng, X., Sun, X., Fan, X., Li, A., Zhang, C., Kang, Y., Liang, Y., & Zhang, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142865 · Cited by 5
Through the heart and beyond: a review on ranolazine
Uran, C. (2021) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2021.1806 · Cited by 4
Singh, D., Oladimeji-Salami, J. A., & Akindele, A. J. (2025) · Experimental Biology and Medicine · doi:10.3389/ebm.2025.10604 · Cited by 2
“In animal models of diabetes, RAN lowered postprandial and basal glucagon concentrations, resulting in a drop in hyperglycemia, demonstrating that RAN ’ s glucose-lowering actions might be achieved via the blocking of sodium channels in pancreatic alpha cells [127].”
Saed, C. T., Dakhili, S. A. T., Greenwell, A. A., Chan, J. S. F., Yang, K., Gopal, K., Eaton, F., Batran, R. A., & Ussher, J. R. (2023) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13906 · Cited by 1
Ahmed, S. Z. E.-A., Mohamed, A. S., Abdullah, O., Sorour, S. M., & Fawzy, E. (2024) · Benha Medical Journal · doi:10.21608/bmfj.2024.265367.2003
“3 isoform of sodium channels in pancreatic α-cells, leading to glucagon and glucose lowering effects in animal models of diabetes [9, 19 and 20].”
BackgroundRavali, R. S., Lakshmi, K. S., Mahalingam, V. T., & Subramonia, K. J. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14016 · Cited by 1
Saed, C. T., Greenwell, A. A., Dakhili, S. A. T., Gopal, K., Eaton, F., & Ussher, J. R. (2021) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0559 · Cited by 2
Ranolazine in Diabetics With Stable Ischemic Heart Disease
Stone, P. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.532 · Cited by 1
Glyco-metabolic Effects of Ranolazine: A truly Multifaceted Drug?
Caminiti, G., Massaro, R., FOSSATI, C., Gatta, L., Selli, S., Sposato, B., & Volterrani, M. (2018) · Journal of Cardiology and Therapy · doi:10.17554/j.issn.2309-6861.2018.05.159
Ravali, R. S., Lakshmi, K. S., Vijayakumar, T. M., & Kumar, J. S. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100359
Managing Stable Coronary Artery Disease in Diabetes
Koulouridis, I., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_23
Investigating the effect of Ranolazine drug on the pathophysiology of asthma in a rat model
Sadeghi, M., Shahrooz, S., Aghamohammadi, M., khodabandeloo, H., Dashatan, N. A., Koushki, M., & Athari, S. S. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07455-1
“It is hypothesized that Ranolazine exerts its anti-diabetic effects by inhibiting glucagon release through Na + channel blockade in pancreatic α-cells [19].”
Metadata
- Authors
- Dhalla, A. K., Yang, M., Ning, Y., Kahlig, K. M., Krause, M., Rajamani, S., & Belardinelli, L.
- Affiliations
- Gilead Sciences (United States) (US)
- Corresponding author
- Dhalla, Arvinder K.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-09-15
- Volume
- 63
- Issue
- 10
- Pages
- 3545-3556
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2151219840
- Cited by
- 53
- References
- 41
- Citations by year
- 2025: 6 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 7 · 2016: 8 · 2015: 4 · 2014: 3
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- ranolazine, Nav1.3, voltage-gated sodium channels, alpha cells, glucagon secretion, type 2 diabetes, antidiabetic mechanism, hyperglycemia, pancreatic islets, intracellular calcium
- MeSH terms
- Ranolazine, Acetanilides, Animals, Diabetes Mellitus, Experimental, Exocytosis, Glucagon, Humans, Hypoglycemic Agents, Islets of Langerhans, Male, Piperazines, Rats, Sprague-Dawley, Sodium Channel Blockers, Glucagon-Secreting Cells, Rats, NAV1.3 Voltage-Gated Sodium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.